Cartesian Therapeutics, Inc. (RNAC)
| Market Cap | 373.91M |
| Revenue (ttm) | 26.00M |
| Net Income (ttm) | -219.71M |
| Shares Out | 17.78M |
| EPS (ttm) | -49.80 |
| PE Ratio | n/a |
| Forward PE | 25.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 123,840 |
| Open | 20.98 |
| Previous Close | 20.90 |
| Day's Range | 20.71 - 21.74 |
| 52-Week Range | 11.67 - 42.60 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 27.67 (+31.57%) |
| Earnings Date | May 10, 2024 |
About RNAC
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; an... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for RNAC stock is "Strong Buy." The 12-month stock price forecast is $27.67, which is an increase of 31.57% from the latest price.
News
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
GAITHERSBURG, Md.--(BUSINESS WIRE)--Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today annou...
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GAITHERSBURG, Md.--(BUSINESS WIRE)--Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today annou...
Cartesian Therapeutics Announces New Employment Inducement Grants
GAITHERSBURG, Md.--(BUSINESS WIRE)--Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune d...
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
Proposals approved at Company's special meeting of stockholders held March 27, 2024 Proposals approved at Company's special meeting of stockholders held March 27, 2024
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on track for mid-2024
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune dis...
Cartesian Therapeutics Announces New Employment Inducement Grant
GAITHERSBURG, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatme...
Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
New facility expected to support expanded cGMP manufacturing of clinical and commercial supply of Company's pipeline of mRNA cell therapies for the treatment of autoimmune diseases
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) and Encourages Investors to Contact the Firm
PHILADELPHIA , Jan. 18, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Cartesian Therapeutics, Inc. (NASDAQ: RNAC) ("Cartesian"), formerly known as Selecta Biosciences, Inc. (...